BioStock: Elicera’s CEO: “All signs of the disease disappeared in the first patient”
The first patient has been treated in Elicera Therapeutics’ CARMA study and the results are highly promising. After one month of follow-up, the patient achieved a complete response with very mild side effects. The data was presented at the scientific conference Cancer Crosslinks on January 23. BioStock spoke with CEO Jamal el-Mosleh to get his thoughts.
Read the article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/